Cargando…

Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics

The tyrosine kinase inhibitor sunitinib is an effective first-line treatment for patients with advanced renal cell carcinoma (RCC). Hypothesizing that a functional read-out by mass spectrometry-based (phospho, p-)proteomics will identify predictive biomarkers for treatment outcome of sunitinib, tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Wijngaart, Hanneke, Beekhof, Robin, Knol, Jaco C., Henneman, Alex A., de Goeij-de Haas, Richard, Piersma, Sander R., Pham, Thang V., Jimenez, Connie R., Verheul, Henk M. W., Labots, Mariette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631096/ https://www.ncbi.nlm.nih.gov/pubmed/37940875 http://dx.doi.org/10.1186/s12014-023-09437-6

Ejemplares similares

Advancing wide implementation of precision oncology: A liquid nitrogen‐free snap freezer preserves molecular profiles of biological samples
por: van der Wijngaart, Hanneke, et al.
Publicado: (2023)

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2022)

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
por: Beekhof, Robin, et al.
Publicado: (2019)

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
por: Labots, Mariette, et al.
Publicado: (2020)

Peptide-mediated ‘miniprep’ isolation of extracellular vesicles is suitable for high-throughput proteomics
por: Knol, Jaco C., et al.
Publicado: (2016)

Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells
por: Poel, Dennis, et al.
Publicado: (2019)

Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines
por: Glykofridis, Iris E., et al.
Publicado: (2022)

Effects of Cancer Presence and Therapy on the Platelet Proteome
por: Walraven, Maudy, et al.
Publicado: (2021)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients
por: Buffart, Tineke E., et al.
Publicado: (2021)

Quantitative Phosphoproteomic Analysis Reveals Dendritic Cell- Specific STAT Signaling After α2-3–Linked Sialic Acid Ligand Binding
por: Li, Rui-Jún Eveline, et al.
Publicado: (2021)

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors
por: Gerritse, Sophie L., et al.
Publicado: (2022)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies
por: Cordo’, Valentina, et al.
Publicado: (2022)

Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture
por: Rajcevic, Uros, et al.
Publicado: (2014)

Whole gel processing procedure for GeLC-MS/MS based proteomics
por: Piersma, Sander R, et al.
Publicado: (2013)

Cancer cells copy migratory behavior and exchange signaling networks via extracellular vesicles
por: Steenbeek, Sander C, et al.
Publicado: (2018)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014)

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors
por: Cucchi, David G. J., et al.
Publicado: (2021)

Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling
por: Voortman, Johannes, et al.
Publicado: (2009)

Combining radiotherapy with sunitinib: lessons (to be) learned
por: Kleibeuker, Esther A., et al.
Publicado: (2015)

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance
por: Rausch, Magdalena, et al.
Publicado: (2020)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
por: Azijli, Kaamar, et al.
Publicado: (2015)

Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
por: Labots, Mariette, et al.
Publicado: (2018)

iq: an R package to estimate relative protein abundances from ion quantification in DIA-MS-based proteomics
por: Pham, Thang V, et al.
Publicado: (2020)

Longitudinal stability of urinary extracellular vesicle protein patterns within and between individuals
por: Erozenci, Leyla A., et al.
Publicado: (2021)

Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2016)

Proteomic Profiling of Mycobacterium tuberculosis Identifies Nutrient-starvation-responsive Toxin–antitoxin Systems
por: Albrethsen, Jakob, et al.
Publicado: (2013)

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
por: Walraven, Maudy, et al.
Publicado: (2018)

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
por: Kleibeuker, Esther A, et al.
Publicado: (2015)

Feasibility of urinary extracellular vesicle proteome profiling using a robust and simple, clinically applicable isolation method
por: Bijnsdorp, Irene V., et al.
Publicado: (2017)

Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling
por: Verweij, Frederik Johannes, et al.
Publicado: (2018)

Correction: Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling
por: Verweij, Frederik Johannes, et al.
Publicado: (2018)

Selective targeting of ligand-dependent and -independent signaling by GPCR conformation-specific anti-US28 intrabodies
por: De Groof, Timo W. M., et al.
Publicado: (2021)

Secreted protein markers in oral squamous cell carcinoma (OSCC)
por: Mumtaz, Madiha, et al.
Publicado: (2022)

Redetermined structure of diphenylphosphonimidotriphenylphosphorane: location of the hydrogen atoms and analysis of the intermolecular interactions
por: Betz, Richard, et al.
Publicado: (2011)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sbt1pp34s0qrimt2p8h5qd02jb